tirzepatide being banned has been officially removed from the FDA shortage list FDA Bans Compounded Tirzepatide! What

The normalization of intestinal permeability, while not formally included among STRIDE-II targets, represents a desirable future endpoint that may further refine the assessment of barrier restoration

For example, if you enrolled on April 14th, your billing date will be the 14th of each month moving forward

The FDA issued a warning in June 2026 calling compounded versions "potentially risky for patients." Despite that warning, compounded GLP-1 products remain in use, partly because they cost significantly less than brand-name alternatives

But the marketing will matter

Additional important safety considerations include monitoring for gallbladder disease, acute kidney injury with dehydration, and diabetic retinopathy (particularly with rapid A1c reduction)